Practical Radiation Oncology

PRO 05 - PRO - ASTRO Science Review 2018

Lung: LBA10 - PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Saturday, October 20
4:55 PM - 5:07 PM
Location: Room 304

George Rodrigues, MD, PhD, FASTRO

London Health Sciences Centre

Disclosure:
Employment
George Rodrigues Medicine Professional Corporation: President: Independent Contractor; London Health Sciences Centre: Faculty: Employee

Ownership
Demos Medical Publishing: Royalty; George Rodrigues Medicine Professional Corporation: Stock

Biography:
George Rodrigues MD PhD FRCPC FASTRO is a clinician scientist in radiation oncology at the Lawson Health Research Institute and London Health Sciences Centre. He has consulted on and provides radiation treatment for patients with genitourinary and thoracic cancers as well as brain metastases since 2001 after his graduation from the University of Toronto Radiation Oncology Residency Program. He is a former award-winning Residency Program Director and currently sits on various boards and committees for ASTRO, CARO, and NRG Oncology. He is academically appointed to the departments of radiation oncology and epidemiology/biostatistics and has several doctoral, master’s, and post-graduate trainees under his supervision. He has attained both a M.Sc. degree in Clinical Epidemiology and Biostatistics (Thesis - Health Related Quality of Life) and a Ph.D. degree in Medicine (Thesis - Brain Metastases). His current research interests include: clinical trial design, evidence synthesis, “big-data” statistical analysis, and multisite arc-based hypofractionated radiotherapy.

Presentation(s):

Send Email for George Rodrigues


Assets

Lung: LBA10 - PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Lung: LBA10 - PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC